MedTrace Logo

A Prospective Randomised Control Trial to Study the Effectiveness of a Health Service Innovation Using a Modified Virtual Ward Model to Prevent Unscheduled Readmission of High Risk Patients

NCT02325752 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 840

Last updated 2017-02-10

No results posted yet for this study

Summary

The investigators conducted an open randomized control study of patients who received the transitional care program versus patients who received usual care at the Singapore General Hospital from Aug 2011 to Sept 2012.

Conditions

Interventions

OTHER

Intervention

A multidisciplinary team delivered the transitional care program. Our transitional care program focused on four key areas: 1. Post discharge surveillance of the patient to ensure adherence to care plans. 2. Coordination of follow-up visits with specialist care providers. 3. Patent education and care giver training. 4. Activation of community and social services. Upon recruitment, the patients were interviewed and assessed by the team nurse prior to their discharge. Intervention starts upon discharge from the hospital. The duration of the intervention program was 3 months. A follow-up by telephone was made within 72 hours after discharge to assess patient's condition and adherence to treatment plan. Home visits were made within 2 weeks after discharge.

Sponsors & Collaborators

  • Agency for Integrated Care, Singapore

    collaborator OTHER

  • Duke-NUS Graduate Medical School

    collaborator OTHER

  • Singapore General Hospital

    lead OTHER

Principal Investigators

  • Kheng Hock Lee, MBBS · Singhealth Foundation

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2012-10-31
Completion
2013-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02325752 on ClinicalTrials.gov